Table 3 JBI quality appraisal results
[29] | [32] | [22] | [30] | [23] | [24] | [25] | [33] | [28] | [35] | [31] | [34] | [26] | [27] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Is there a well-defined question? | Y* | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | U* | Y | Y |
2. Is there comprehensive description of alternatives? | Y | U | Y | Y | Y | Y | Y | Y | Y | Y | Y | R* | R | R |
3. Are all important and relevant costs and outcomes for each alternative identified? | Y | Y | Y | N* | U | Y | Y | N | U | Y | U | N | N | Y |
4. Has clinical effectiveness been established? | U | U | Y | Y | Y | Y | Y | N | U | Y | Y | N | Y | Y |
5. Are costs and outcomes measured accurately? | Y | U | Y | Y | U | Y | Y | Y | U | Y | Y | N | N | Y |
6. Are costs and outcomes valued credibly? | Y | U | Y | Y | U | Y | Y | N | Y | Y | Y | N | N | Y |
7. Are costs and outcomes adjusted for differential timing? | N | N | U | N | N | Y | U | N | Y | Y | Y | N | N | Y |
8. Is there an incremental analysis of costs and consequences? | N | N | Y | N | N | Y | N | N | N | Y | Y | N | N | Y |
9. Were sensitivity analyses conducted to investigate uncertainty in estimates of cost or consequences? | Y | N | N | N | N | N | N | N | N | Y | Y | N | N | Y |
10. Do study results include all issues of concern to users? | Y | N | Y | Y | U | Y | Y | U | U | Y | Y | N | N | Y |
11. Are the results generalizable to the setting of interest in the review? | Y | Y | Y | Y | Y | Y | Y | U | U | Y | Y | N | N | Y |